Search results

Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

21 March 2018

Evidence-based recommendations on avelumab (Bavencio) with axitinib for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

8 January 2026

In development Reference number: GID-TA11186 Expected publication date: TBC

Result type

Technology appraisal guidance

Status

In development

Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

10 April 2024

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

24 March 2022

Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

30 September 2020

Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

11 January 2023

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

3 October 2018

This guideline covers diagnosing and managing renal cell carcinoma in people aged 18 and over. It aims to improve care by helping healthcare professionals offer people the right treatments and support, taking into account the person’s individual preferences.

Result type

NICE guideline

Published

19 March 2026